Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 17.5 USD 2.52%
Market Cap: $224.4m

Operating Margin

-112.6%
Current
Declining
by 38.7%
vs 3-y average of -73.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-112.6%
=
Operating Income
$-23.6m
/
Revenue
$20.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-112.6%
=
Operating Income
$-23.6m
/
Revenue
$20.9m

Peer Comparison

Country Company Market Cap Operating
Margin
IL
Mediwound Ltd
NASDAQ:MDWD
224.4m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
220.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.2B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.4B USD
Loading...

Market Distribution

Lower than 85% of companies in Israel
Percentile
15th
Based on 734 companies
15th percentile
-112.6%
Low
-84 760% — -5.8%
Typical Range
-5.8% — 10.9%
High
10.9% — 23 869.1%
Distribution Statistics
Israel
Min -84 760%
30th Percentile -5.8%
Median 4%
70th Percentile 10.9%
Max 23 869.1%

Mediwound Ltd
Glance View

Market Cap
224.4m USD
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

MDWD Intrinsic Value
7.38 USD
Overvaluation 58%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-112.6%
=
Operating Income
$-23.6m
/
Revenue
$20.9m
What is Mediwound Ltd's current Operating Margin?

The current Operating Margin for Mediwound Ltd is -112.6%, which is below its 3-year median of -73.9%.

How has Operating Margin changed over time?

Over the last 3 years, Mediwound Ltd’s Operating Margin has decreased from -68.6% to -112.6%. During this period, it reached a low of -112.6% on Oct 30, 2025 and a high of -28.2% on Dec 31, 2022.

Back to Top